Eli Lilly’s crop of new products propelled the ... for the firm was likely the resilience of its diabetes blockbuster Trulicity. Trulicity (dulaglutide) grew more than expected to reach $1.2 ...

Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Eli Lilly sees Trulicity and Taltz sales supporting 2020 sales growth, and forecasts stronger-than-expected earnings in the coming financial year. Eli Lilly & Co. (LLY) shares traded higher ...

Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what its prospects are for the next ...

This pushed Lilly to raise its sales outlook for the year by $2 billion, despite short revenue from diabetes treatments Mounjaro and Trulicity. Analysts noted Eli Lilly and its biggest rival ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

For years, Eli Lilly's business has relied heavily on top-selling diabetes drug Trulicity for growth. But with the approval of Mounjaro for diabetes and Zepbound for weight loss, it's a much ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...

Eli Lilly said also said sales of its blockbuster diabetes treatment, Trulicity, rose 24% from last year to $1.502 billion. Earlier this month, Eli Lilly said its developing coronavirus ...

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...

Eli Lilly’s crop of new products propelled the ... for the firm was likely the resilience of its diabetes blockbuster Trulicity. Trulicity (dulaglutide) grew more than expected to reach $1.2 ...